{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:15:38Z","timestamp":1776935738896,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00391-021-01907-6","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T16:23:17Z","timestamp":1623342197000},"page":"507-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antirheumatic drugs in older adults and polypharmacy issues","Antirheumatika bei \u00e4lteren Erwachsenen und die Probleme der Polypharmazie"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-5969","authenticated-orcid":false,"given":"Ilke","family":"Coskun Benlidayi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-6452","authenticated-orcid":false,"given":"Yesim","family":"Gokce Kutsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"2","key":"1907_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5770\/cgj.23.393","volume":"23","author":"R Akter","year":"2020","unstructured":"Akter\u00a0R, Maksymowych\u00a0WP, Martin\u00a0ML, Hogan\u00a0DB (2020) Outcomes with biological disease-modifying anti-rheumatic drugs (bDMARDs) in older patients treated for rheumatoid arthritis. Can Geriatr\u00a0J 23(2):184\u2013189. https:\/\/doi.org\/10.5770\/cgj.23.393","journal-title":"Can Geriatr J"},{"issue":"16","key":"1907_CR2","doi-asserted-by":"publisher","first-page":"e19696","DOI":"10.1097\/MD.0000000000019696","volume":"99","author":"N Alpay-Kanitez","year":"2020","unstructured":"Alpay-Kanitez\u00a0N, Pehlivan \u00d6, Omma\u00a0A et al (2020) Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis. Medicine 99(16):e19696. https:\/\/doi.org\/10.1097\/MD.0000000000019696","journal-title":"Medicine"},{"issue":"10","key":"1907_CR3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman\u00a0K, Subesinghe\u00a0S, Norton\u00a0S, Atzeni\u00a0F, Galli\u00a0M, Cope\u00a0AP, Winthrop\u00a0KL, Galloway\u00a0JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Baillieres Clin Rheumatol 58(10):1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Baillieres Clin Rheumatol"},{"issue":"10","key":"1907_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman\u00a0K, Clarke\u00a0BD, Rutherford\u00a0AI et\u00a0al (2019) Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Baillieres Clin Rheumatol 58(10):1767\u20131776. https:\/\/doi.org\/10.1093\/rheumatology\/kez037","journal-title":"Baillieres Clin Rheumatol"},{"issue":"3","key":"1907_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.rdc.2018.03.010","volume":"44","author":"BY Betancourt","year":"2018","unstructured":"Betancourt\u00a0BY, Biehl\u00a0A, Katz\u00a0JD, Ananta Subedi\u00a0A (2018) Pharmacotherapy pearls in rheumatology for the care of older adult patients: focus on oral disease-modifying antirheumatic drugs and the newest small molecule inhibitors. Rheum Dis Clin North Am 44(3):371\u2013391. https:\/\/doi.org\/10.1016\/j.rdc.2018.03.010","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"1907_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel (2019) American Geriatrics Society 2019 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults. J\u00a0Am Geriatr Soc 67(4):674\u2013694. https:\/\/doi.org\/10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"1907_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.sapharm.2018.08.012","volume":"15","author":"J Conklin","year":"2019","unstructured":"Conklin\u00a0J, Farrell\u00a0B, Suleman\u00a0S (2019) Implementing deprescribing guidelines into frontline practice: barriers and facilitators. Res Social Adm Pharm 15(6):796\u2013800. https:\/\/doi.org\/10.1016\/j.sapharm.2018.08.012","journal-title":"Res Social Adm Pharm"},{"key":"1907_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00296-019-04264-1","volume":"39","author":"I Coskun Benliday\u0131","year":"2019","unstructured":"Coskun Benliday\u0131\u00a0I (2019) Polypharmacy in geriatric rheumatology. Rheumatol Int 39:1115\u20131116. https:\/\/doi.org\/10.1007\/s00296-019-04264-1","journal-title":"Rheumatol Int"},{"issue":"10","key":"1907_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00296-020-04618-0","volume":"40","author":"I Coskun Benlidayi","year":"2020","unstructured":"Coskun Benlidayi\u00a0I (2020) The effectiveness and safety of electrotherapy in the management of fibromyalgia. Rheumatol Int 40(10):1571\u20131580. https:\/\/doi.org\/10.1007\/s00296-020-04618-0","journal-title":"Rheumatol Int"},{"issue":"3","key":"1907_CR10","first-page":"390","volume":"35","author":"JR Curtis","year":"2017","unstructured":"Curtis\u00a0JR, Schulze-Koops\u00a0H, Takiya\u00a0L et al (2017) Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol 35(3):390\u2013400","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1907_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.semarthrit.2018.07.009","volume":"48","author":"DS Dalal","year":"2019","unstructured":"Dalal\u00a0DS, Duran\u00a0J, Brar\u00a0T et al (2019) Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to young: a systematic review and meta-analysis. Semin Arthritis Rheum 48(5):799\u2013807. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.009","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1907_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40266-019-00653-0","volume":"36","author":"AL Day","year":"2019","unstructured":"Day\u00a0AL, Singh\u00a0JA (2019) Cardiovascular disease risk in older adults and elderly patients with rheumatoid arthritis: what role can disease-modifying antirheumatic drugs play in cardiovascular risk reduction? Drugs Aging 36(6):493\u2013510. https:\/\/doi.org\/10.1007\/s40266-019-00653-0","journal-title":"Drugs Aging"},{"issue":"5","key":"1907_CR13","doi-asserted-by":"publisher","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","volume":"14","author":"K Ebina","year":"2019","unstructured":"Ebina\u00a0K, Hashimoto\u00a0M, Yamamoto\u00a0W et\u00a0al (2019) Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis\u2014The ANSWER cohort study. PLoS ONE 14(5):e216624. https:\/\/doi.org\/10.1371\/journal.pone.0216624","journal-title":"PLoS ONE"},{"issue":"4","key":"1907_CR14","first-page":"445","volume":"15","author":"S Eyigor","year":"2012","unstructured":"Eyigor\u00a0S, Gokce Kutsal\u00a0Y (2012) Polypharmacy in the elderly: to prescribe or not prescribe \u201cthat is the question\u201d. Turk J Geriatr 15(4):445\u2013454","journal-title":"Turk J Geriatr"},{"issue":"1","key":"1907_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.sapharm.2017.01.003","volume":"14","author":"B Farrell","year":"2018","unstructured":"Farrell\u00a0B, Richardson\u00a0L, Raman-Wilms\u00a0L, de Launay\u00a0D, Alsabbagh\u00a0MW, Conklin\u00a0J (2018) Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Res Social Adm Pharm 14(1):18\u201325. https:\/\/doi.org\/10.1016\/j.sapharm.2017.01.003","journal-title":"Res Social Adm Pharm"},{"issue":"7","key":"1907_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jamda.2009.03.018","volume":"10","author":"Y Gokce Kutsal","year":"2009","unstructured":"Gokce Kutsal\u00a0Y, Barak\u00a0A, Atalay\u00a0A et\u00a0al (2009) Polypharmacy in the elderly: a\u00a0multicenter study. J\u00a0Am Med Dir Assoc 10(7):486\u2013490. https:\/\/doi.org\/10.1016\/j.jamda.2009.03.018","journal-title":"J Am Med Dir Assoc"},{"key":"1907_CR17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200310","author":"JG Hanly","year":"2020","unstructured":"Hanly\u00a0JG, Lethbridge\u00a0L (2020) Disease modifying anti-rheumatic drugs, biologics and corticosteroid use in older patients with rheumatoid arthritis over 20\u00a0years. J\u00a0Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.200310","journal-title":"J Rheumatol"},{"issue":"12","key":"1907_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/pds.3354","volume":"21","author":"LJ Herrinton","year":"2012","unstructured":"Herrinton\u00a0LJ, Liu\u00a0L, Chen\u00a0L et al (2012) Association between anti-TNF\u2011\u03b1 therapy and all-cause mortality. Pharmacoepidemiol Drug Saf 21(12):1311\u20131320. https:\/\/doi.org\/10.1002\/pds.3354","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1907_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s10067-011-1845-8","volume":"30","author":"A Juby","year":"2011","unstructured":"Juby\u00a0A, Davis\u00a0P (2011) An evaluation of the impact of seniors on a\u00a0rheumatology referral clinic: demographics and pharmacotherapy. Clin Rheumatol 30(11):1507\u20131509. https:\/\/doi.org\/10.1007\/s10067-011-1845-8","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1907_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.semarthrit.2018.07.006","volume":"48","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz\u00a0AJ, Cohen\u00a0S, Keystone\u00a0EA et al (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a\u00a0Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 48(3):406\u2013415. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.07.006","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1907_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski\u00a0SL, Neogi\u00a0T, Hochberg\u00a0MC et\u00a0al (2020) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 72(2):220\u2013233. https:\/\/doi.org\/10.1002\/art.41142","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1907_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/rheumatology\/key165","volume":"58","author":"C Lahaye","year":"2019","unstructured":"Lahaye\u00a0C, Tatar\u00a0Z, Dubost\u00a0JJ, Tournadre\u00a0A, Soubrier\u00a0M (2019) Management of inflammatory rheumatic conditions in the elderly. Rheumatology 58(5):748\u2013764. https:\/\/doi.org\/10.1093\/rheumatology\/key165","journal-title":"Rheumatology"},{"issue":"1","key":"1907_CR23","first-page":"29","volume":"36","author":"L Leon","year":"2018","unstructured":"Leon\u00a0L, Gomez\u00a0A, Vadillo\u00a0C et al (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36(1):29\u201335","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"1907_CR24","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/cells9081876","volume":"9","author":"M Massalska","year":"2020","unstructured":"Massalska\u00a0M, Maslinski\u00a0W, Ciechomska\u00a0M (2020) Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: latest updates and potential strategy for fighting COVID-19. Cells 9(8):1876\u20131811. https:\/\/doi.org\/10.3390\/cells9081876","journal-title":"Cells"},{"issue":"7","key":"1907_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/acr2.11064","volume":"1","author":"G Ozen","year":"2019","unstructured":"Ozen\u00a0G, Pedro\u00a0S, England\u00a0BR, Mehta\u00a0B, Wolfe\u00a0F, Michaud\u00a0K (2019) Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs. ACR Open Rheumatol 1(7):424\u2013432. https:\/\/doi.org\/10.1002\/acr2.11064","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"1907_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00002512-200320090-00006","volume":"20","author":"A Pilotto","year":"2003","unstructured":"Pilotto\u00a0A, Franceschi\u00a0M, Leandro\u00a0G, Di Mario\u00a0F, Geriatric Gastroenterology Study Group (Societ\u00e8 Italiana Gerontologie Geriatria) (2003) NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 20(9):701\u2013710. https:\/\/doi.org\/10.2165\/00002512-200320090-00006","journal-title":"Drugs Aging"},{"issue":"8","key":"1907_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","volume":"37","author":"S Rajasimhan","year":"2020","unstructured":"Rajasimhan\u00a0S, Pamuk\u00a0O, Katz\u00a0JD (2020) Safety of Janus kinase inhibitors in older patients: a focus on the thromboembolic risk. Drugs Aging 37(8):551\u2013558. https:\/\/doi.org\/10.1007\/s40266-020-00775-w","journal-title":"Drugs Aging"},{"issue":"10","key":"1907_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr2.11083","volume":"1","author":"MD Richter","year":"2019","unstructured":"Richter\u00a0MD, Matteson\u00a0EL, Davis\u00a0JM 3rd, Achenbach\u00a0SJ, Crowson\u00a0CS (2019) Comparison of biologic discontinuation in patients with elderly-onset versus younger-onset rheumatoid arthritis. ACR Open Rheumatol 1(10):627\u2013631. https:\/\/doi.org\/10.1002\/acr2.11083","journal-title":"ACR Open Rheumatol"},{"key":"1907_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05372-1","author":"A Sood","year":"2020","unstructured":"Sood\u00a0A, Raji\u00a0MA (2020) Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-05372-1","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1907_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","volume":"33","author":"T Sugihara","year":"2016","unstructured":"Sugihara\u00a0T, Harigai\u00a0M (2016) Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging 33(2):97\u2013107. https:\/\/doi.org\/10.1007\/s40266-015-0341-2","journal-title":"Drugs Aging"},{"issue":"12","key":"1907_CR31","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00228-015-1954-4","volume":"71","author":"E Tommelein","year":"2015","unstructured":"Tommelein\u00a0E, Mehuys\u00a0E, Petrovic\u00a0M, Somers\u00a0A, Colin\u00a0P, Boussery\u00a0K (2015) Potentially inappropriate prescribing in community-dwelling older people across Europe: a\u00a0systematic literature review. Eur J Clin Pharmacol 71(12):1415\u20131427. https:\/\/doi.org\/10.1007\/s00228-015-1954-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1907_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14336\/AD.2017.0306","volume":"9","author":"S Wongrakpanich","year":"2018","unstructured":"Wongrakpanich\u00a0S, Wongrakpanich\u00a0A, Melhado\u00a0K, Rangaswami\u00a0J (2018) A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis 9(1):143\u2013150. https:\/\/doi.org\/10.14336\/AD.2017.0306","journal-title":"Aging Dis"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-021-01907-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00391-021-01907-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-021-01907-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T19:08:26Z","timestamp":1663960106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00391-021-01907-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1907"],"URL":"https:\/\/doi.org\/10.1007\/s00391-021-01907-6","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"value":"0948-6704","type":"print"},{"value":"1435-1269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.\u00a0Coskun Benlidayi and Y.\u00a0Gokce Kutsal declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}